Rheumatology Medical News about Rituximab;anti-synthetase syndrome

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Rituximab treatment of the anti-synthetase syndrome—a retrospective case series
Rheumatology, 06/22/09

Sem M et al. – This retrospective case series indicates a short-term beneficial effect of rituximab in anti-synthetase syndrome (ASS). Prospective, controlled studies are needed to validate this finding and further assess safety issues.

Methods

A retrospective case series to assess ASS pts with interstitial lung disease (ILD) treated with rituximab
11 ASS pts; data on clinical and laboratory parameters, lung imaging by high-resolution CT thorax and pulmonary function tests were collected, 6 mo pre-treatment, and 3 and 6 mo post-treatment

Results

All 11 ASS pts had severe and progressive ILD and most of them had previously failed on cyclophosphamide and/or other immuno-modulating agents
Rituximab appeared to stabilize and/or improve the ILD in 7/11 ASS pts during the first 6 mo after treatment
Rituximab treatment appeared to decrease the serum level of anti-Jo-1 Ab, but the decrease was most often modest
One patient developed a fatal infection 3 mo after the last infusion with rituximab
In the other ASS pts, the treatment was well tolerated

<< Previous
Certolizumab pegol for rheumatoid arthritis: Effective in...

Next >>
Vitamin D in systemic lupus erythematosus: Potential beyond bone...